Heart Health Blood Tests

Quick answer

Heart risk is assessed with a core panel (lipid profile, blood pressure, blood sugar) plus advanced markers like troponin for heart muscle injury, NT-proBNP for heart strain, and Lp(a), a genetically set risk factor statins cannot lower. The core takeaway: one-off numbers matter less than your 10-year calculated risk, which decides whether treatment is worthwhile.

The core cardiac risk blood panel

Test	Optimal	Borderline/High	Why it matters
Total Cholesterol	<200 mg/dL	200–239 / ≥240	Overall lipid burden
LDL Cholesterol	<100 mg/dL (<70 if very high risk)	130–159 / ≥160	The main statin target; builds arterial plaque
HDL Cholesterol	>60 mg/dL	40–60 / <40 (men)	Protective; removes cholesterol from arteries
Triglycerides	<150 mg/dL	150–199 / ≥200	Raised by carbs, alcohol, diabetes
Fasting Glucose	70–100 mg/dL	100–125 (pre-diabetes)	Diabetes doubles heart risk
HbA1c	<5.7%	5.7–6.4% (pre-diabetes)	3-month blood sugar average
hs-CRP	<1.0 mg/L (low risk)	1.0–3.0 (moderate)	Vascular inflammation

Key points

Core panel: lipid profile, blood pressure, blood sugar; advanced markers include troponin, NT-proBNP and Lp(a).
Lp(a) is genetically set and not lowered by statins; check it once.
NT-proBNP above 125 pg/mL with breathlessness strongly suggests heart failure.
10-year risk calculators decide whether treatment is worthwhile.

Advanced cardiac biomarkers

Lipoprotein(a): Lp(a)

Lp(a) is a genetically determined atherogenic lipoprotein that increases heart attack and stroke risk independently of LDL. It is not reduced by statins. Optimal: <30 mg/dL. About 20% of the population has elevated Lp(a). It should be measured at least once in every adult, especially those with premature heart disease or a family history of heart attack before age 60. Newer drugs specifically targeting Lp(a) are in development.

Homocysteine

Elevated homocysteine (>15 micromol/L) is associated with increased cardiovascular risk, stroke and venous thrombosis. It rises with B12 and folate deficiency, hypothyroidism, kidney disease, and genetic MTHFR mutations. Supplementing B12 and folate lowers homocysteine but has not been proven to reduce cardiovascular events in large trials.

NT-proBNP / BNP

The heart failure markers. NT-proBNP >125 pg/mL in a patient with breathlessness strongly suggests heart failure. Used in: diagnosing heart failure, monitoring treatment, and as a prognostic marker.² A completely normal NT-proBNP makes significant heart failure very unlikely.

High-sensitivity Troponin (hs-cTn)

The definitive heart attack test. A single negative hs-troponin at presentation, followed by a second negative at 1–3 hours, rules out acute MI with >99% sensitivity. Also mildly elevated in heart failure, pulmonary embolism, myocarditis and after intense exercise.

10-year cardiovascular risk calculators

Rather than treating each test result in isolation, doctors calculate your overall 10-year cardiovascular risk using validated calculators: ASCVD Pooled Cohort Equations (USA), SCORE2 (Europe), QRISK3 (UK). These combine: age, sex, smoking status, blood pressure, cholesterol, diabetes status and ethnicity to estimate your 10-year risk of heart attack or stroke. Treatment decisions (whether to start statins, aspirin, etc.) are largely based on this overall risk, not individual test values alone.

How often to test

Test	Frequency
Fasting lipid profile	Every 5 years from age 20; annually if on statins or history of heart disease
Fasting glucose / HbA1c	Every 3 years if normal; annually if pre-diabetic or high-risk
hs-CRP	Once: guides statin decision in borderline-risk patients
Lp(a)	Once in a lifetime (genetically determined)
NT-proBNP	Only if symptoms of heart failure

Questions to ask your doctor

What is my 10-year cardiovascular risk?
Should I be on a statin?
What is my Lp(a) level?
Is my hs-CRP elevated?
What lifestyle changes will lower my cardiac risk most effectively?

Troponin, the gold standard for heart muscle injury

Cardiac troponin T and troponin I are structural proteins found exclusively in the myocardium (heart muscle). When heart cells die, as in myocardial infarction (MI), troponin is released into the bloodstream. High-sensitivity troponin (hs-cTnT or hs-cTnI) assays can detect troponin at concentrations 10–100 times lower than previous generation tests, enabling diagnosis of MI earlier and with greater precision.

The high-sensitivity era has changed the 0/3-hour and 0/1-hour rapid MI rule-out algorithms. A troponin rise and fall pattern (at least one value above the 99th centile of a healthy population, with a significant change between serial measurements) is required to diagnose type 1 MI (plaque rupture), a single elevated troponin without a dynamic pattern may indicate chronic myocardial injury (heart failure, CKD, myocarditis, pulmonary embolism) rather than an acute event.

BNP and NT-proBNP, markers of cardiac stretching

B-type natriuretic peptide (BNP) and its inactive precursor fragment (NT-proBNP) are released by ventricular myocytes in response to wall stress, caused by volume or pressure overload. They are the most diagnostically useful blood tests for heart failure, with critical rule-out and rule-in values:

NT-proBNP below 125 pg/mL (or BNP below 35 pg/mL): Heart failure is highly unlikely. The negative predictive value approaches 99% in the NICE-recommended diagnostic pathway.
NT-proBNP above 2000 pg/mL (or BNP above 400 pg/mL): Acute decompensated heart failure is likely; immediate echocardiography and treatment is indicated.
NT-proBNP 125–2000 pg/mL: Intermediate range, echocardiography is required to confirm or exclude heart failure.

Natriuretic peptides are also elevated by atrial fibrillation, pulmonary embolism, right heart failure, and severe renal impairment, they are not heart-failure-specific. Obesity reduces BNP levels (adipose tissue clears BNP); values in obese patients may underestimate heart failure severity.

The lipid panel and cardiovascular risk

The standard lipid panel (total cholesterol, HDL, LDL, triglycerides) is combined with blood pressure, diabetes status, and other risk factors in the QRISK3 calculator to generate a 10-year cardiovascular risk score. A score above 10% triggers a NICE recommendation to offer statin therapy. However, for patients with established cardiovascular disease (prior MI, stroke, stable angina, or peripheral arterial disease), statins are recommended regardless of baseline cholesterol, the risk-reduction benefit is proven at all cholesterol levels in this population. The target in established CVD: LDL below 2.0 mmol/L or at least 50% LDL reduction from baseline, using high-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg).³

Your next steps for heart risk testing

Start with the core panel
Get a fasting lipid profile plus fasting glucose / HbA1c. These seven numbers (total cholesterol, LDL, HDL, triglycerides, glucose, HbA1c, hs-CRP) carry most of the predictive weight.
Check Lp(a) once in your life
Lipoprotein(a) is genetically fixed and not lowered by statins. About one person in five has an elevated level, so a single measurement covers you permanently.
Get your 10-year risk calculated
Ask your doctor for an ASCVD, SCORE2 or QRISK3 score. A score above the treatment threshold is what decides whether a statin is worthwhile — not any single lipid value in isolation.
Know the symptom-driven markers for what they are
Troponin and NT-proBNP are acute-care tests for chest pain and breathlessness, not routine screening. NT-proBNP above 125 pg/mL with breathlessness strongly suggests heart failure and needs follow-up.
Retest on a schedule, not at random
Lipids every five years from age 20 (annually on statins), glucose every three years if normal, hs-CRP and Lp(a) once. Calendar-based retesting makes results comparable.

Core cardiac risk panel at a glance

The core panel below is the workhorse of heart risk assessment. Advanced markers like Lp(a), homocysteine, troponin and NT-proBNP answer specific follow-up questions.

Test	Target	Borderline / high	Why it matters
Total cholesterol	<200 mg/dL	200–239 / ≥240	Overall lipid burden
LDL cholesterol	<100 mg/dL (<70 if very high risk)	130–159 / ≥160	Main statin target; builds arterial plaque
HDL cholesterol	>60 mg/dL	40–60 / <40 (men)	Protective; clears cholesterol from arteries
Triglycerides	<150 mg/dL	150–199 / ≥200	Raised by refined carbs, alcohol, diabetes
Fasting glucose	70–100 mg/dL	100–125 (pre-diabetes)	Diabetes roughly doubles heart risk
HbA1c	<5.7%	5.7–6.4% (pre-diabetes)	Three-month blood sugar average
hs-CRP	<1.0 mg/L (low risk)	1.0–3.0 (moderate)	Vascular inflammation; guides statin decisions

Practical notes

Before the test, tell the lab and your doctor about all medicines, supplements (especially biotin, niacin, and fish oil), caffeine, and any recent heavy exercise, illness, or alcohol intake — each of these can move lipid, hs-CRP, or troponin readings. Ask whether the lipid panel should be fasting and what time of day your doctor prefers the draw.

Bring previous lipid reports so trends are visible — a trend matters as much as any single value — along with home blood-pressure readings if you track them, your family history of heart disease, and the exact list of cholesterol or blood-pressure medicines you take.

Read the numbers in context: cholesterol is one piece of cardiovascular risk alongside age, blood pressure, smoking, diabetes, and family history, which feed into the risk calculators your doctor uses. A high single number is not a diagnosis, and a normal one is not a clean bill of health — ask your doctor what your overall risk estimate looks like.

For follow-up, ask when each test should be repeated (lipids are often rechecked a few weeks after a change and then on a schedule your doctor sets), what result would trigger a change in plan, and which symptoms — such as chest discomfort or unusual breathlessness — should bring you back sooner than scheduled.

In India

A basic lipid profile is typically ₹500–₹1,200; broader heart packages that add hs-CRP, Lp(a), or an ECG/echo run higher, typically ₹2,000–₹8,000, though prices vary by city and lab. Compare the included tests, not just the headline price.

Choose NABL-accredited labs for cardiac panels, and note that home sample collection is available in major cities. The reference range printed on your own report is the one that counts — methods and ranges differ between labs, so do not judge your values against a generic table.

Frequently Asked Questions

What is Lp(a), and why should I be tested for it once?

Lp(a), or lipoprotein(a), is a genetically determined atherogenic lipoprotein that raises heart attack and stroke risk independently of LDL cholesterol. It is not reduced by statins. About 20% of people have an elevated level (optimal is under 30 mg/dL), and because levels barely change through life, a single measurement is enough to know where you stand.

How do 10-year cardiovascular risk calculators work?

Rather than treating each test in isolation, calculators like the ASCVD Pooled Cohort Equations (USA), SCORE2 (Europe) and QRISK3 (UK) combine age, sex, smoking status, blood pressure, cholesterol, diabetes status and ethnicity into one 10-year probability of a heart attack or stroke. That score, not any single lipid value, is what treatment decisions are based on.

What is troponin, and when is it tested?

Cardiac troponin T and troponin I are structural proteins found only in heart muscle. When heart cells die, as in a heart attack, troponin leaks into the blood. High-sensitivity troponin assays can rule out an acute heart attack with over 99% sensitivity when two measurements taken 1–3 hours apart are both negative. It is mildly raised in some other conditions too, so it is interpreted in context.

What do BNP and NT-proBNP measure?

BNP and NT-proBNP are released by the heart's ventricles in response to wall stress from volume or pressure overload. They are the most diagnostically useful blood tests for heart failure: NT-proBNP below 125 pg/mL makes heart failure highly unlikely, while values above 2000 pg/mL make it likely and urgent to evaluate. They also rise in atrial fibrillation, pulmonary embolism and severe kidney impairment, so they are not heart-failure-specific.

How is the lipid panel used to assess cardiovascular risk?

The lipid panel (total cholesterol, HDL, LDL, triglycerides) is combined with blood pressure, diabetes status and other factors in a risk calculator to produce a 10-year cardiovascular risk score. A score above 10% on QRISK3, for example, triggers a guideline recommendation to discuss statin therapy. The single calculated risk matters more for treatment decisions than any one lipid number.

My cholesterol came back ‘high’ — does that mean I need medicine?

Not automatically. Doctors weigh the number against your overall risk — age, blood pressure, smoking, diabetes, and family history all count. Some people start with lifestyle changes and a retest; others at higher risk may need treatment sooner. The decision belongs to your doctor, ideally after discussing your risk score with you.

Should I stop my statin before the lipid test to get a ‘true’ reading?

No — your doctor wants the reading on your current treatment, because it shows whether the treatment is working. Stopping a statin without medical advice can be risky. Tell the lab you are taking one and keep taking it unless your doctor says otherwise.

Do I need an ECG every time my lipids are checked?

Not usually. Blood tests and ECGs answer different questions — lipids show risk factors, while an ECG shows the heart's current electrical activity. Your doctor decides when each is due; discuss the right rhythm for both at your visit.

My father had a heart attack at 50 — what should I ask my doctor?

Mention it at the start of the visit. A family history often moves screening earlier and broadens it — your doctor may order Lp(a) once, use a risk calculator, and set a lower threshold for follow-up. Bring details: the age at the event, which relative it was, and what treatment they received.

References

Sources cited on this page. PubMed links open the original abstract.

Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. PMID 28527533 · doi:10.1016/j.jacc.2017.04.052
Netala VR, Zhang Z. "Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis." Int J Mol Sci. 2025;26(7):3218. PMID 40244022 · doi:10.3390/ijms26073218
Netala VR, Zhang Z. "A Comprehensive Review of Cardiovascular Disease Management." Cells. 2024;13(17):1471. PMID 39273041 · doi:10.3390/cells13171471

Medical Disclaimer: This page is for general educational purposes only and does not constitute medical advice. Always consult a qualified doctor for diagnosis and treatment.